BioDetego is dedicated to the development and commercialization of the next generation of cancer diagnostics.
BioDetego is an early-stage company dedicated to the development and commercialization of the next generation of cancer diagnostics – identifying who needs chemotherapy better than traditional staging or molecular diagnostics. Today there are no clear treatment guidelines for many cancer patients and routinely patients are undertreated (the lack of chemotherapy treatment for patients at risk of developing metastasis) and overtreated (the unnecessary, harmful treatment of patients not at risk). The resulting human and economic burden is substantial. Patients who are undertreated face increased mortality at a cost of >$50,000/patient recurrence, whereas overtreated patients suffer harmful side-effects of unnecessary chemotherapy at a cost of >$25,000/patient.
Supported by compelling clinical data, BioDetego is developing VASPfore, a powerful cancer diagnostic platform that addresses this critical gap in patient management. The lead product, VASPfore-CRC, will:
• Accurately determine metastatic risk in colorectal cancer patients
• Provide physicians with 100% actionable information to reduce harmful undertreatment and overtreatment of patients
• Offer payors enormous savings (>$150MM) by reducing treatment costs and improving patient outcomes.
Expansion of the platform beyond colorectal cancer is under development with an ongoing preliminary clinical study in breast cancer and planned studies in additional cancers.